A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function

Impaired Renal Function Clinical Trial

Official title:

A Phase 1 Study to Evaluate the Pharmacokinetics of Roxadustat in Subjects With Different Degrees of Renal Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02965040
• Other study ID #: 1517-CL-0543
• Secondary ID: 2015-002565-28
• Status: Completed
• Phase: Phase 1
• Start date: December 12, 2016
• Est. completion date: December 11, 2017

Study information

• Verified date: February 2020
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

For subjects with normal renal function or severely impaired renal function, this study will evaluate the pharmacokinetics of roxadustat and its main metabolites in plasma and urine.

For subjects with end stage renal disease (ESRD) on continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD), this study will evaluate the pharmacokinetics of roxadustat and its main metabolites in plasma, urine and dialysate.

For subjects with ESRD on hemodialysis (HD) or hemodiafiltration (HDF), this study will evaluate the pharmacokinetics of roxadustat and its main metabolites in plasma, urine and dialysate and also the effect of dialysis on the pharmacokinetics of roxadustat and its main metabolites.

Description:

This is a phase 1, open-label study in two sites. There will be four different renal function groups.

For all subjects:

Subjects will be allocated to the normal and severely impaired renal function groups based on estimated glomerular filtration rate (eGFR), calculated with the abbreviated modification of diet in renal disease (MDRD) equation. The eGFR will be based on the serum creatinine concentration and is assessed at screening and at day -2. The eGFR obtained at screening will determine the allocation.

Subjects will be allocated to the ESRD groups based on their dialysis requirements.

Subjects with normal and severely impaired renal function, and subjects with ESRD on CAPD or APD:

Screening will take place from day -30 to day -3 and the subjects will be admitted to the clinical unit on day -2. The treatment period lasts 8 days, during which the subjects will receive a single oral dose of roxadustat in the morning of day 1 Subjects will complete the treatment period on day 6, provided that all required assessments have been performed and there are no medical reasons for a prolonged follow-up. The study will be completed with an end-of-study visit (ESV), which will take place between 5 and 9 days after the last treatment period-defined assessment (or after early withdrawal).

Subjects with ESRD on HD or HDF:

Screening will take place from day -30 to day -3 and subjects will complete 2 treatment periods of 8 days (period 1) and 7 days (period 2) in order to evaluate the pharmacokinetics of roxadustat with a single oral dose of roxadustat on day 1 of both periods after and before dialysis.

Subjects will complete the treatment period 1 on day 6 followed by a wash-out period which is minimally 1 week and maximally 3 weeks. Subjects will complete period 2 on day 6, provided that all required assessments have been performed and there are no medical reasons for a prolonged follow-up. The study will be completed with an end-of-study visit (ESV), which will take place between 5 and 9 days after the last treatment period-defined assessment (or after early withdrawal).

All subjects:

Safety assessments will be performed throughout the study. An optional biobanking sample may be taken for potential exploratory, retrospective, gene polymorphism analysis. Roxadustat plasma, urine, and dialysate samples will be stored for potential exploratory metabolic profiling or exploratory biomarker analysis after the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: December 11, 2017
• Est. primary completion date: December 4, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

Inclusion criteria for all subjects:

• Subject has a body weight of 45 to 160 kg, inclusive.

• For subjects with ESRD on CAPD or APD body weight should be recorded as the measured body weight minus abdominal dialysis fluid based on the last filling. For subjects with ESRD on HD or HDF the post-dialysis body weight will be recorded.

Specific inclusion criteria for subjects with normal renal function:

• Subject is a healthy male or female subject aged 40 to 75 years, inclusive.

• Subject must have a pre-dose eGFR value based on the abbreviated MDRD method of greater than or equal to 90 mL/min/1.73 m^2.

Specific inclusion criteria for subjects with severely impaired renal function:

• Subject is a male or female subject aged 18 to 75 years, inclusive.

• Subject must have a pre-dose eGFR value based on the abbreviated MDRD method [screening] of <30 mL/min/1.73 m^2 and not be on dialysis.

Specific inclusion criteria for subjects with ESRD on CAPD or APD:

• Subject is a male or female subject aged 18 to 75 years, inclusive.

• Subject is on CAPD or APD treatment with the same mode of dialysis for at least 4 months prior to admission to the clinical unit.

Specific inclusion criteria for subjects with ESRD on HD or HDF:

• Subject is a male or female subject aged 18 to 75 years, inclusive.

• Subject is on HD or HDF treatment with the same mode of dialysis for at least 4 months prior to admission to the clinical unit and should have dialysis sessions three times weekly.

Specific inclusion criteria for subjects with impaired renal function including severly impaired renal function and ESRD:

• If a subject is being treated with short-acting ESAs, the subject agrees to discontinue treatment for at least 14 days prior to admission.

Exclusion Criteria:

Exclusion criteria for all subjects:

• Subject has a known or suspected hypersensitivity to Roxadustat or any components (e.g., lactose) of the formulations used.

• Subject has any clinically significant history of allergic conditions (including drug allergies or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

• Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (noncutaneous) infection within 1 week prior to admission to the clinical unit.

• Subject has any clinically significant abnormality following the investigator's review of the physical examination, electrocardiogram (ECG), and clinical study protocol-defined clinical laboratory tests at screening or day -2.

• Subject has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit.

• Subject has a history of drinking more than 21 units (male subjects) or more than 14 units (female subjects) of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) within 3 months prior to admission to the clinical unit.

• Subject uses moderate or strong inducers of metabolism (e.g., barbiturates, rifampin) regularly in the 1 month prior to admission to the clinical unit.

• Subject must not consume grapefruit (or any grapefruit-containing products, including juice) or Seville oranges (or any Seville orange-containing products, including juice) within 7 days prior to admission to the clinical unit.

• Subject uses any drugs of abuse within 3 months prior to admission to the clinical unit.

• Subject has a positive serology test for hepatitis B surface antigen (HBsAg), anti-hepatitis A virus (immunoglobulin M [IgM]), anti-hepatitis C virus, hepatitis B core antibody or anti-human immunodeficiency virus (HIV) type 1 or 2 [screening].

• Subject participated in any clinical study or has been treated with any investigational drugs within 28 days (or 5 half-lives whichever is longer), prior to screening.

• Subject has any condition which makes the subject unsuitable for clinical study participation.

• Subject is a vulnerable subject (e.g., subject kept in detention).

Specific exclusion criteria for subjects with normal renal function:

• Subjects aged greater than or equal to 40 and < 65:

• Subject has a mean pulse < 45 or >90 bpm; mean systolic blood pressure <90 mmHg and >140 mmHg; mean diastolic blood pressure <50 mmHg and >90 mmHg at day -2. Vital signs measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically. If the mean pulse, systolic blood pressure or diastolic blood pressure exceeds the limits above, 1 additional triplicate can be taken [day -2].

• Subjects aged greater than or equal to 65 and less than or equal to 75:

• Subject has a mean pulse <45 or >90 bpm; mean systolic blood pressure <90 mmHg and >160 mmHg; mean diastolic blood pressure <50 mmHg and >100 mmHg at day -2. Vital signs measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically. If the mean pulse, systolic blood pressure or diastolic blood pressure exceeds the limits above, 1 additional triplicate can be taken [day -2].

• Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, psychiatric, dermatologic, renal and/or other major disease or malignancy.

• Subjects aged greater than or equal to 40 and <65:

• Subject has a mean corrected QT interval using Fridericia's formula (QTcF) >430 ms (for males) and >450 ms (for females) at day 2. If the mean QTcF exceeds the limits above, 1 additional triplicate Electrocardiogram (ECG) can be taken (day -2).

• Subjects aged greater than or equal to 65 and less than or equal to 75:

• Subject has a mean QTcF >450 ms (for males) and >470 ms (for females) at day 2. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken (day -2).

• Subject has any of the liver chemistry tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], gamma-glutamyl transferase [GGT] and total bilirubin [TBL]) above 1.5 times the upper limit of normal (ULN) at day -2. In such a case, the assessment may be repeated once [day -2].

• Subject uses any prescribed or non-prescribed drugs (including vitamins, calcium, magnesium and iron supplements, natural- and herbal- remedies, e.g., St. John's Wort) within 2 weeks (or 5 half-lives, whichever is longer) prior to admission to the clinical unit, except for occasional use of paracetamol (up to 2 g per day) and oral contraceptives or hormone replacement therapy.

Specific exclusion criteria for subjects with impaired renal function (including severely impaired renal function and ESRD):

• Subject has a mean pulse <45 or >90 bpm; mean systolic blood pressure <90 mmHg and >160 mmHg; mean diastolic blood pressure <50 mmHg and >100 mmHg at day -2. Vital signs measurements, taken in triplicate after the subject has been resting in supine position for 5 minutes; pulse will be measured automatically. If the mean pulse, systolic blood pressure or diastolic blood pressure exceeds the limits above, 1 additional triplicate can be taken [day -2].

• Subject has a history of any clinically significant illness (other than renal disease and conditions related to the renal disease, such as stable diabetes and stable hypertension), medical condition, or laboratory abnormality within 3 months prior to screening that would preclude participation in the clinical study.

• Subject has used immunosuppressant drugs or drugs used to treat malignancies (including corticosteroids at doses >10 mg prednisolone per day or equivalent) within 3 months prior to admission to the clinical unit.

• Subject is anticipated to undergo surgery that is expected to lead to significant blood loss during the clinical study period or anticipated coronary revascularization.

• Subject has an anticipated use of the following prohibited medication during the treatment and/or follow-up of the study:

• Oral multivalent cation-containing drugs and mineral supplements (e.g., iron, calcium, magnesium, aluminium), anion-exchange resins (e.g., colestyramine), sucralfate or magnesium- or aluminium-containing antacids, phosphate binders, and iron-chelating agents are not allowed from 24 hours before until 48 hours after dosing.

• Short-acting intravenous (IV) or subcutaneous (SC) Erythropoiesis stimulating agents (ESA) are not allowed within 2 weeks prior to admission to the clinical unit until the ESV.

• Dapsone in any dose amount or anticipated chronic use of paracetamol >2 g/day or nonsteroidal anti-inflammatory drugs (NSAIDs), except for low dose aspirin/acetylsalicylic acid, is not allowed from admission to the clinical unit until the ESV.

• Subject has not been on a stable dose of concomitant medication to treat concurrent chronic conditions for at least 2 weeks (or 5 half-lives of the drug, whichever is longer) prior to admission to the clinical unit (minor dose changes are allowed in agreement with Sponsor). Doses of statins should not exceed the capped maximum daily doses at admission to the clinical unit. Rosuvastatin use is not allowed.

• Subject who requires, or is likely to require, any new concomitant medication from the time of screening until the ESV.

• Subject has used any non-essential prescribed and non-prescribed drugs (including vitamins, natural- and herbal-remedies (e.g., St. John's Wort) within 2 weeks (or 5 half-lives, whichever is longer) prior to admission to the clinical unit.

• Subject has a mean QTcF >450 ms (for males) and >470 ms (for females) at day 2. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken (day -2).

• Subject who has renal disease secondary to malignancy.

• Subject who has a fluctuating or rapidly deteriorating renal function within 4 weeks prior to admission to the clinical unit, as indicated by strongly varying or worsening of clinical and/or laboratory signs of renal impairment within the screening period.

• Subject with serum uric acid >2 x the ULN. In such a case the assessment may be repeated once [day -2].

• Subject with any of the liver chemistry tests (AST, ALT and TBL) out of range as indicated below. In such a case the assessment may be repeated once [day -2].

• ALT or AST >3 x ULN

• TBL >1.5 x ULN

• Subject has had any prior organ transplant (that has not been explanted) or subject is scheduled for organ transplantation.

Related Conditions & MeSH terms

• Impaired Renal Function
• Normal Renal Function
• Renal Insufficiency

Intervention

Drug:
• Roxadustat
Oral

Locations

Country	Name	City	State
Germany	Site DE49001	Munchen
United Kingdom	Site GB44001	Liverpool

Sponsors (2)

Lead Sponsor	Collaborator
Astellas Pharma Europe B.V.	FibroGen

Countries where clinical trial is conducted

Germany,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics of Roxadustat in plasma: Cmax	Cmax: Maximum concentration	Up to day 6
Primary	Pharmacokinetics of Roxadustat in plasma: Cmax,u	Cmax,u: Maximum concentration of unbound compound	Up to day 6
Primary	Pharmacokinetics of Roxadustat in plasma: AUCinf	AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity	Up to day 6
Primary	Pharmacokinetics of Roxadustat in plasma: AUCinf,u	AUCinf,u: Area under the concentration-time curve from the time of dosing extrapolated to time infinity for unbound concentration	Up to day 6
Primary	Pharmacokinetics of Roxadustat in plasma: AUClast	AUClast: Area under the concentration-time curve from the time of dosing to the last measurable concentration (Clast)	Up to day 6
Primary	Pharmacokinetics of Roxadustat in plasma: AUClast,u	AUClast,u: Area under the concentration-time curve from the time of dosing to the last measurable concentration (Clast) for unbound concentration	Up to day 6
Primary	Pharmacokinetics of Roxadustat in plasma: CL/F	CL/F: Apparent total systemic clearance after single or multiple extravascular dosing	Up to day 6
Primary	Pharmacokinetics of Roxadustat in plasma: CLu/F	CLu/F: Apparent total systemic clearance of unbound compound after extravascular dosing	Up to day 6
Primary	Pharmacokinetics of Roxadustat in plasma: fu	fu: Fraction of parent or metabolite available systemically unbound (= free fraction)	Up to day 6
Primary	Pharmacokinetics of Roxadustat in plasma: tmax	tmax: Time of the maximum concentration	Up to day 6
Primary	Pharmacokinetics of Roxadustat in plasma t1/2	t1/2: Terminal elimination half-life	Up to day 6
Primary	Pharmacokinetics of Roxadustat in plasma: Vz/F	Vz/F: Apparent volume of distribution during the terminal elimination phase after single extravascular dosing	Up to day 6
Primary	Pharmacokinetics of Roxadustat in plasma: Vz,u/F	Vz,u/F: Apparent volume of distribution during the terminal elimination phase of unbound compound after extravascular dosing	Up to day 6
Primary	Pharmacokinetics of O-glucuronide-Roxadustat in plasma: Cmax		Up to day 6
Primary	Pharmacokinetics of O-glucuronide-Roxadustat in plasma: AUCinf		Up to day 6
Primary	Pharmacokinetics of O-glucuronide-Roxadustat in plasma: AUClast		Up to day 6
Primary	Pharmacokinetics of O-glucuronide-Roxadustat in plasma: tlag	tlag: Time prior to the time corresponding to the first measurable (non-zero) concentration	Up to day 6
Primary	Pharmacokinetics of O-glucuronide-Roxadustat in plasma: tmax		Up to day 6
Primary	Pharmacokinetics of O-glucuronide-Roxadustat in plasma: t1/2		Up to day 6
Primary	Pharmacokinetics of O-glucuronide-Roxadustat in plasma: MPR	MPR: Metabolite to parent ratio of AUC using AUC (corrected) for the metabolite (corrected by molecular weight ratio of parent to metabolite)	Up to day 6
Primary	Pharmacokinetics of O-glucoside -Roxadustat in plasma: Cmax		Up to day 6
Primary	Pharmacokinetics of O-glucoside-Roxadustat in plasma: AUCinf		Up to day 6
Primary	Pharmacokinetics of O-glucoside-Roxadustat in plasma: AUClast		Up to day 6
Primary	Pharmacokinetics of O-glucoside-Roxadustat in plasma: tlag	tlag: Time prior to the time corresponding to the first measurable (non-zero) concentration	Up to day 6
Primary	Pharmacokinetics of O-glucoside-Roxadustat in plasma: tmax		Up to day 6
Primary	Pharmacokinetics of O-glucoside-Roxadustat in plasma: t1/2		Up to day 6
Primary	Pharmacokinetics of O-glucoside-Roxadustat in plasma: MPR	MPR: Metabolite to parent ratio of AUC using AUC(corrected) for the metabolite (corrected by molecular weight ratio of parent to metabolite)	Up to day 6
Primary	Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: Cmax		Up to day 6
Primary	Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: AUCinf		Up to day 6
Primary	Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: AUClast		Up to day 6
Primary	Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: tlag	tlag: Time prior to the time corresponding to the first measurable (non-zero) concentration	Up to day 6
Primary	Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: tmax		Up to day 6
Primary	Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: t1/2		Up to day 6
Primary	Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: MPR		Up to day 6
Primary	Pharmacokinetics of Roxadustat in urine: CLR	CLR: Renal clearance	Up to day 4
Primary	Pharmacokinetics of Roxadustat in urine: CLR,u	CLR,u: Renal clearance of unbound drug	Up to day 4
Primary	Pharmacokinetics of Roxadustat in urine: Aeinf	Aeinf: Cumulative amount of compound excreted into urine from time of dosing extrapolated to time infinity	Up to day 4
Primary	Pharmacokinetics of Roxadustat in urine: Aeinf%	Aeinf%: Percent of drug dose excreted into urine (Aeinf) from time of dosing extrapolated to time infinity	Up to day 4
Primary	Pharmacokinetics of Roxadustat in urine: Aelast	Aelast: Cumulative amount of drug excreted into urine from time of dosing up to the collection time of the last measurable concentration	Up to day 4
Primary	Pharmacokinetics of Roxadustat in urine: Aelast%	Aelast%: Percent of drug dose excreted into urine (Aelast) from time of dosing up to the collection time of the last measurable concentration	Up to day 4
Primary	Pharmacokinetics of O-glucuronide-Roxadustat in urine: CLR		Up to day 4
Primary	Pharmacokinetics of O-glucuronide-Roxadustat in urine: Aeinf		Up to day 4
Primary	Pharmacokinetics of O-glucuronide-Roxadustat in urine: Aelast		Up to day 4
Primary	Pharmacokinetics of O-glucuronide-Roxadustat in urine: MPR based on Aeinf		Up to day 4
Primary	Pharmacokinetics of O-glucoside-Roxadustat in urine: CLR		Up to day 4
Primary	Pharmacokinetics of O-glucoside-Roxadustat in urine: Aeinf		Up to day 4
Primary	Pharmacokinetics of O-glucoside-Roxadustat in urine: Aelast		Up to day 4
Primary	Pharmacokinetics of O-glucoside-Roxadustat in urine: MPR based on Aeinf		Up to day 4
Primary	Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: CLR		Up to day 4
Primary	Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: Aeinf		Up to day 4
Primary	Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: Aelast		Up to day 4
Primary	Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: MPR based on Aeinf		Up to day 4
Primary	Pharmacokinetics of Roxadustat and its main metabolites in dialysate fluid: CLD	CLD: dialysis clearance. For ESRD subjects on CAPD or APD and for ESRD subjects on HD or HDF (treatment period 2 only)	Up to day 2
Primary	Pharmacokinetics of Roxadustat in dialysate fluid: fD	fD: fraction of dose cleared by dialysis. For ESRD subjects on CAPD or APD and for ESRD subjects on HD or HDF (treatment period 2 only)	Up to day 2
Primary	Pharmacokinetics of O-glucuronide-Roxadustat in urine: Aeinf%		Up to day 4
Primary	Pharmacokinetics of O-glucoside-Roxadustat in urine: Aeinf%		Up to day 4
Primary	Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: Aeinf%		Up to day 4
Primary	Pharmacokinetics of Roxadustat in plasma: Effective t½ 48 hours	Effective t½ 48 hours: Effective half-life based on a dosing interval of 48 hours	Up to day 6
Primary	Pharmacokinetics of Roxadustat in plasma: Effective t½ 56 hours	Effective t½ 56 hours: Effective half-life based on a dosing interval of 56 hours	Up to day 6
Primary	Pharmacokinetics of O-glucuronide-Roxadustat in plasma: TER	TER: Total exposure ratio	Up to day 6
Primary	Pharmacokinetics of O-glucoside-Roxadustat in plasma: TER		Up to day 6
Primary	Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: TER		Up to day 6
Secondary	Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): Emax	Emax: Maximum effect	Up to day 6
Secondary	Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): Emax-baseline	Emax-baseline: Maximum effect from baseline	U to day 6
Secondary	Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): AUCE,last	AUCE,last: Area under the effect-time curve from the time of dosing to the last measurable effect	Up to day 6
Secondary	Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): AUCE,last (baseline-corrected)	AUCE,last (baseline-corrected): Area under the effect-time curve from the time of dosing to the last measurable effect baseline corrected	Up to day 6
Secondary	Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): tmax, EPO	tmax, EPO: Time to maximum EPO concentration	Up to day 6
Secondary	Safety assessed by nature, frequency, and severity of Adverse Events (AEs)		Up to End of Study (EOS) (Up to day 15, period 2)
Secondary	Number of participants with vital signs abnormalities and/or adverse events related to treatment	Vital signs include: blood pressure (systolic and diastolic) and pulse	Up to EOS (Up to day 15, period 2)
Secondary	Safety assessed by routine 12- lead electrocardiogram (ECG)	Routine 12-lead ECG measurements will be performed for the different renal function groups, as applicable, after the subject has been in a supine position for at least 5 minutes. All routine 12-lead ECG data will be listed by subject	Up to EOS (Up to day 15, period 2)
Secondary	Safety assessed by continuous heart rate (HR) measurement	Holter	Up to day 2 (period 1)
Secondary	Number of participants with laboratory value abnormalities and/or adverse events related to treatment	Safety laboratory tests include: hematology, biochemistry and urinalysis	Up to EOS (Up to day 15, period 2)

External Links

•   Link to results on Astellas Clinical Study Results website